CGC-11047 is a novel polyamine analog that targets the hyper-proliferating blood vessel growth, known as choroidal neovascularization, associated with age-related macular degeneration (AMD).
The phase I trial is designed to determine the safety and tolerability of CGC-11047 in patients with age-related macular degeneration. A total of fifteen patients will be treated in cohorts of escalating doses. Patients will be treated subconjunctivally, avoiding the need to inject into the eye.
“This is the second indication for CGC-11047 to enter the clinic, and we believe CGC-11047’s potent anti-proliferative properties, distinct mechanism of action and ease of administration will make it an excellent drug candidate for this disease setting,” said Edward Schnipper, president and CEO of Cellgate. “The potential we’ve observed for CGC-11047 to impede the blood vessel growth underlying AMD and to improve vision distinguish it from that of existing treatments.”